Pharmaceutical Executive

By Pharmaceutical Executive PodcastScience Life Sciences

Pharmaceutical Executive episodes

February 10Bets and Balances: Riding the Risk-and-Innovation Pendulum in Biotech
In a podcast conversation with Pharm Exec, Ken Banta, founder and CEO of The Vanguard Network, and Andrew Hall, CEO of Consano Bio, discuss what effective leadership looks like in today’s volatile capital and regulatory climates for emerging biotechs. Part 1 of the conversation explores why Banta and Hall believe CEOs of these companies must act as stabilizers and translators—balancing risk with opportunity and turning complex scientific innovation into clear strategy for investors, regulators, and employees alike.
Highlights of the discussion include:
The EQ imperative: leading through persuasion and influence, not dictates. “It’s not about the science; it’s about the people.”
The best CEOs follow a four-core formula
Early stage’s mindset mix (end-game vs journey)—and the rewards of “failing fast”
Why Series A’s are the “lifeblood of biotech”
18 min
February 09 Pharmaceutical Executive Daily: Hims & Hers Removes Access to New Compounded Semaglutide Pill
In today’s Pharmaceutical Executive Daily, Hims & Hers withdraws access to its compounded semaglutide pill following a controversy filled launch, next-generation trial designs increasingly integrate real-world data, and Eli Lilly enters an $8 billion strategic collaboration involving Innovent and Orna Therapeutics.
2 min
February 06 Pharmaceutical Executive Daily: The Launch of TrumpRx
In today’s Pharmaceutical Executive Daily, TrumpRx officially launches, the FDA moves against mass marketing of illegal copycat drugs, and AI emerges as a force multiplier for small and mid-size biotech companies
2 min
February 05 Pharmaceutical Executive Daily: FDA Approves First and Only Oral Film Treatment for Erectile Dysfunction
In today’s Pharmaceutical Executive Daily, FDA approves Vybrique for erectile dysfunction, experts argue Phase III clinical protocols should be treated as product launch blueprints, and Veradermics completes an upsized $256 million IPO.
2 min
February 04 Pharmaceutical Executive Daily: Susan G. Komen Releases Breast Cancer Outlook for 2026
In today’s Pharmaceutical Executive Daily, Susan G. Komen releases its 2026 breast cancer progress outlook, industry leaders explore how pharma can tap into emerging talent hubs, and Novartis’ Q4 results highlight mounting pressure from its upcoming patent cliff.
2 min
February 03 Pharmaceutical Executive Daily: SanegeneBio's $1.5 Billion License Agreement with Genentech
In today’s Pharmaceutical Executive Daily, a new a is expected to evolve in 2026, the FDA rejects AstraZeneca’s application for a subcutaneous indication of Saphnelo, and SanegeneBio enters a $1 billion global licensing agreement with Genentech focused on RNAi development.
2 min
February 02 Pharmaceutical Executive Daily: FDA Reveals PreCheck Pilot Program
In today’s Pharmaceutical Executive Daily, the FDA introduces a PreCheck pilot program aimed at strengthening domestic manufacturing oversight, an ACIP member alleges FDA leadership halted a decision related to COVID-19 vaccines, and Eli Lilly announces plans for a $3 billion manufacturing facility in Pennsylvania.
2 min
January 30 Pharmaceutical Executive Daily: Public Citizen Sues The Trump Administration Over Undisclosed Drug Price Agreements
In today’s Pharmaceutical Executive Daily, Public Citizen files suit over undisclosed drug pricing agreements involving Pfizer and Eli Lilly, HHS releases new guidance aimed at lowering prescription drug costs through direct-to-consumer programs, and AstraZeneca enters a multibillion-dollar collaboration with CSPC Pharmaceutical Group.
2 min
January 29 Pharmaceutical Executive Daily: The Disconnect Between Pharma and MedTech
In today’s Pharmaceutical Executive Daily, MJH Life Sciences CEO, Mike Hennessy Jr. examines why pharma and medtech still struggle to deliver truly integrated healthcare solutions, questions emerge around U.S. funding tied to global vaccine policy shifts, and the FDA approves a new treatment option for adults with presbyopia.
2 min
January 28 Pharmaceutical Executive Daily: Eli Lilly Enters $1 Billion Research Collaboration with Seamless Therapeutics
In today’s Pharmaceutical Executive Daily, Insilico Medicine and Qilu Pharmaceuticals launch a $120 million collaboration to advance AI-driven cardiometabolic therapies, Eli Lilly enters a billion-dollar research partnership targeting hearing loss, and industry leaders examine what it takes to bring breakthrough rare disease products to patients.
2 min